Skip to content
Homepage
Author:
AbbVie Inc.
Posted Date:
May 28, 2026
U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
AbbVie Inc.
May 28, 2026
U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
AbbVie Inc.
May 28, 2026
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
AbbVie Inc.
May 22, 2026
Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
AbbVie Inc.
May 22, 2026
AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
AbbVie Inc.
May 22, 2026
AbbVie to Present at the Bank of America Securities Healthcare Conference
AbbVie Inc.
May 6, 2026
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
AbbVie Inc.
May 5, 2026
Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month
AbbVie Inc.
April 30, 2026
AbbVie Reports First-Quarter 2026 Financial Results
AbbVie Inc.
April 29, 2026
AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata
AbbVie Inc.
April 29, 2026
1
2
3
…
5
Next
